Core Insights - MannKind Corporation is focused on transforming chronic disease care through innovative solutions for cardiometabolic and orphan lung diseases, with significant growth anticipated in 2026 [1][3] Business Updates - MannKind closed 2025 with a record-setting fourth quarter, surpassing $100 million in net revenue, and completed the acquisition of scPharmaceuticals [2] - The company is preparing for two high-potential product launches in 2026, which are expected to drive long-term value creation [2] Major Catalysts for 2026 - Afrezza (insulin human) Inhalation Powder is a key product with an FDA decision on a label update anticipated by January 23, 2026, which would update the initial dose for mealtime insulin [5] - The FDA has accepted for review the supplemental Biologics License Application for Afrezza in children and adolescents, with a target action date of May 29, 2026, potentially making it the first needle-free insulin option for pediatric patients in over a century [5] - FUROSCIX ReadyFlow Autoinjector has also been accepted for review by the FDA, with a target action date of July 26, 2026, which would deliver an IV-equivalent diuretic dose in under 10 seconds if approved [5] - Nintedanib DPI (MNKD-201) has enrolled its first patient in a Phase 1b study, with further developments expected in 2026 [5] - The company is advancing pre-clinical development for Bumetanide DPI (MNKD-701) and formulating a second dry powder investigational molecule under collaboration with United Therapeutics [5]